Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Use of recombinant S1 spike polypeptide to develop a TCoV-specific antibody ELISA

Maged H. Gomaa a,1, Dongwan Yoo c, Davor Ojkic b, John R. Barta a,*

a Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario N1G 2W1, Canada
b Animal Health Laboratory, University of Guelph, Guelph, Ontario N1G 2W1, Canada
c Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA

1. Introduction

Turkey coronavirus (TCoV, Order Nidovirales, Family Coronaviridae) is a group III coronavirus closely related to infectious bronchitis virus (IBV) of chickens (Gomaa et al., 2008a). TCoV is an important infectious cause of diarrhoea in turkey poults that negatively impacts rate of growth and efficiency of feed utilization often associated with significant economic losses. Although TCoV was identified as the causative agent of ‘Bluecomb disease’ of turkey poults over 50 years ago (Tumlin et al., 1957), vaccines are not yet available to control the disease. In previous studies seroprevalence of TCoV was determined using virus neutralization (Pomeroy et al., 1975), fluorescent antibody tests (Patel et al., 1976) and ELISAs (Guy et al., 1997; Ali and Reynolds, 1998; Breslin et al., 2001). Some TCoV isolates can be propagated in turkey embryos (Pomeroy et al., 1975), but the virus cannot be propagated in cell culture (Guy et al., 1997; Ali and Reynolds, 1998; Breslin et al., 2001). This appeared to be one of the impediments for development of TCoV detection assays and more comprehensive prevalence studies, because there is not a convenient source of TCoV antigen. There is a high degree of conservation of the nucleocapsid protein among IBV isolates and between IBV and TCoV (Williams et al., 1992; Loa et al., 2000; Gomaa et al., 2008a) making assays based on this protein cross-reactive with other coronaviruses. Thus, even antigens other than TCoV have been used including IBV whole virus antigen in an antibody ELISA (Loa et al., 2004; Gomaa et al., 2008b) and
N-protein produced in a baculovirus expression system has been used in a competitive ELISA (Guy et al., 2002).

Four major structural proteins are produced by most coronaviruses: spike (S) glycoprotein, consisting of two subunits (S1, including a signal peptide domain), membrane (M) protein, small envelope (E) protein, and nucleocapsid (N) protein. The most variable of these molecules is the spike glycoprotein (Gomaa et al., 2009a). For IBV, the S protein is approximately 180 kDa and undergoes post-translational modifications to yield two subunits, the N-terminal S1 subunit of 90 kDa and the C-terminal S2 subunit of 84 kDa (Cavanagh, 1983; Weiss and Martin, 2005). The S1 subunit carries the neutralizing epitopes and plays an important role in the attachment of the virus to the host cell membrane, induction of antibodies for virus neutralization and haemagglutination-inhibition, and induction of IBV-specific cytotoxic T lymphocytes (Kant et al., 1992; Ignjatovic and Galli, 1994). Vaccination with S1 protein protected chickens against IBV challenge but vaccination with the M or N proteins did not (e.g., Ignjatovic and Galli, 1994; Song et al., 1998). Assuming that antibody responses to the S1 protein are similarly important for protection against TCoV, assays measuring antibodies against the spike glycoprotein, particularly S1, would be expected to be a better predictor of protective antibody responses to TCoV than assays based on IBV whole virus or recombinant TCoV nucleocapsid protein alone.

The objective of this study was to develop and validate an ELISA for TCoV based on a recombinant spike polypeptide antigen produced in Escherichia coli. This recombinant S-based antibody ELISA was then used to determine the seroprevalence of TCoV in breeder and meat turkey flocks in Ontario, Canada, and its performance was compared with a previously described recombinant TCoV-N protein-based ELISA (Gomaa et al., 2008b) and an IBV whole virus-based ELISA (e.g., Loa et al., 2000).

2. Materials and methods

2.1. Virus

Turkey coronavirus (TCoV-MG10) was obtained from an Ontario turkey farm suffering from severe cases of acute enteritis and diarrhoea (Gomaa et al., 2008a). This TCoV could not be propagated successfully in cell culture or in embryonated turkey eggs. Therefore, all RNA isolations and subsequent RT-PCR amplifications were conducted on a single filtrate obtained from the intestinal tissue of one turkey culled from this flock that was suffering from clinical disease consistent with TCoV. Briefly, intestinal tissue from this single infected bird was homogenized in 0.9% phosphate-buffered saline (PBS) and then clarified by centrifugation at 4000 × g for 15 min. The supernatant was filtered sequentially through 0.45 μm and 0.22 μm membrane filters (Millipore, Bedford, MA) and stored at −80 °C until use. The presence of TCoV in the filtrate was confirmed using negatively stained filtrate and transmission electron microscopy as well as RT-PCR of a portion of the nucleocapsid gene (Gomaa et al., 2009a). Extensive testing of the resulting TCoV-MG10 filtrate was done to exclude the possibility of the presence of any pathogens other than TCoV using electron microscopy as well as culture for bacteria, other viruses and mycoplasmas (Gomaa et al., 2009b).

The complete genomic sequence for the TCoV-MG10 isolate is available in GenBank (NC_010800, see Gomaa et al., 2008a). To provide an estimate of viral concentration, the TCoV-MG10 suspension was titrated by RT-PCR using primers specific for the nucleocapsid gene (see Gomaa et al., 2009a). Virus-containing suspension diluted 10⁻⁸ was able to produce a weak PCR product of the expected 330 bp in size. To ensure uniformity, the same TCoV-containing filtrate was used throughout this study for both RNA isolation and experimental infection of turkey poult.

2.2. Experimental turkeys

Day-old turkey poult were obtained from a high biosecurity primary breeder facility (Hybrid Turkey, Kitchener, ON, Canada). Although the poult themselves were not tested specifically for the presence of Salmonella, Mycoplasma and other pathogens, this breeder routinely tests for Salmonella and Mycoplasma; thus, the poult are considered free of Salmonella and Mycoplasma. Birds were housed and handled in accordance with guidelines established by the Canadian Council on Animal Care and the Animal Care Committee of the University of Guelph within the Campus Animal Facility's Isolation Unit. Poult were fed and watered ad libitum.

2.3. Control positive and negative turkey serum samples

Forty, day-old poult were separated into two groups of 20 birds. TCoV-MG10 was inoculated orally into 20 birds in one room at 2 days of age, while 20 were maintained in a separate room as negative controls. Infections were confirmed by testing cloacal swabs for TCoV by amplification of a 330 bp fragment of the TCoV nucleocapsid gene using reverse-transcription polymerase chain reaction (Gomaa et al., 2009a). Cloacal swabs were collected from all birds before inoculation and again at days 1, 3, 5, 7, 14 and 21 days post-inoculation. All inoculated birds shed TCoV by 7 days post-inoculation and 50% of the birds continued shedding until 14 days post-inoculation; none of the control turkey poult shed TCoV at any time throughout the study (Gomaa et al., 2009a).

Serum samples were obtained from both groups of birds at days 0, 7, 14, 20, 35 and 42 post-inoculation. All sera were heat-inactivated at 56 °C for 30 min before use. Fifteen specific-pathogen free (SPF) turkey serum samples were kindly provided by Dr. Billy Hargis (University of Arkansas, Fayetteville, AR), and they were used as additional negative controls.

2.4. Selection and cloning of the TCoV-S54–395 protein gene

Antigenic epitope prediction within the TCoV-S1 gene was accomplished using Beta turn prediction (Chou and Fasman, 1987), Emini surface accessibility scale (Emini et al., 1985) antigenicity scale (Kolaskar and Tongaonkar, 1987) and other pathogenic events for bacteria, other viruses and mycoplasmas (Gomaa et al., 2009b).
S54–395 insert was subcloned into competent E. coli BL21 by mixing the plasmid with competent cells on ice for 30 min followed by a 45 s heat shock in a 42 °C waterbath. After 1 h of incubation at 37 °C with gentle agitation, bacteria were plated onto LB agar plates containing ampicillin (0.1 mg/ml). Plasmid DNA was extracted from transformed clones and screened by digestion with BamHI and EcoRI. Clones containing inserts were checked for orientation by sequencing. For protein expression, plasmid DNA containing a confirmed S54–395 insert was subcloned into competent E. coli BL21 by mixing the plasmid with competent cells on ice for 30 min followed by a 45 s heat shock in a 42 °C waterbath. After 1 h of incubation at 37 °C with gentle agitation, bacteria were plated onto LB agar plates containing ampicillin (0.1 mg/ml) ampcillin and incubated overnight at 37 °C. Again, plasmid DNA was extracted from transformed clones and screened by digestion with BamHI and EcoRI. Clones containing inserts were checked for orientation and reading frame by sequencing.

2.5. Expression and purification of S54–395–GST fusion protein

E. coli BL21 containing the truncated S1 gene pGEX-S54–395 was propagated in LB broth containing ampicillin (0.1 mg/ml) overnight at 37 °C with vigorous shaking. One milliliter of overnight culture was inoculated into 100 ml of fresh LB with ampicillin (0.1 mg/ml). When OD600 reached 0.6, the culture was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The culture was incubated for 4 additional hours at 30 °C with shaking. Bacteria were harvested by centrifugation at 6000 rpm for 15 min at 4 °C (Beckman, Coulter, J2-MC centrifuge, Mississauga, ON, Canada). The supernatant was decanted and the pellet was re-suspended in 5 ml of phosphate-buffered saline (PBS).

Purification of the GST fusion protein was conducted by adding 0.5 ml lysozyme solution (12 mg of lysozyme in 50 mM glucose, 10 mM EDTA, 25 mM Tris–HCl, pH 8.0) containing 1 mM phenylmethylsulphonyl fluoride (PMSF). The suspension was sonicated three times for 2 s on ice. Addition of 250 μl of 20% Triton X-100 preceded incubation for 30 min at 4 °C with gentle agitation followed by centrifugation at 10,000 rpm for 10 min at 4 °C. The supernatant was collected and 100 μl of 50% slurry glutathione Sepharose was added to the supernatant (GE Health Care, Buckinghamshire, UK). The suspension was clarified by washing three times with PBS and centrifuged to pellet the Sepharose beads. Cold reduced glutathione was used to elute the bound protein and the eluate was collected from the supernatant after centrifugation of the suspension. Purified recombinant protein was separated using 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and stained with Coomassie blue G-250 (Bio-Rad, Hercules, CA). The purified S54–395 peptide product was separated from its GST fusion partner by thrombin protease using RediPack columns according to the manufacturer’s instructions (GE Health Care, Buckinghamshire, UK).

2.6. Western blot of the TCoV-S54–395 protein

Purified TCoV-S54–395–GST fusion protein was separated using 12% SDS-PAGE and transferred onto nitrocellulose membrane (0.45 μm, Bio-Rad) using the Bio-Rad Mini Trans-blot cell. The membrane was washed 3 times in Tween-20 Tris-buffered saline (TTBS) and then blocked with 5% bovine serum albumin (BSA, Sigma Co., St. Louis, MO) in TTBS overnight at 4 °C with gentle agitation. The membrane was then incubated with goat anti-GST antibody (GE Health Care, Buckinghamshire, UK) for 2 h at 4 °C, followed by incubation with rabbit anti-goat IgG conjugated with alkaline phosphatase (AP, Jackson Immune Research Laboratories Inc., West Grove, Penn) for 2 h at 4 °C. The membrane was washed 3 times with TTBS, and color was developed according to the manufacturer’s instructions (Bio-Rad, Hercules, CA). The cleaved and purified TCoV-S54–395 protein was likewise subjected to Western blot analysis as described using anti-GST antibodies as well as with turkey sera raised against TCoV-MG10 in experimental animals.

2.7. ELISA optimization

A checkerboard titration was conducted using different coating antigen concentrations (12.5, 25, 50, 100 and 200 ng/μl). To determine optimal antibody dilutions, serum samples diluted at 1:50, 1:100, 1:250, 1:500 and 1:1000 were tested with secondary AP-conjugated antibody diluted at 1:1000, 1:2000, 1:5000 and 1:10,000. The ELISAs were all conducted as follows: GST-cleaved S54–395 protein diluted in 0.1 M carbonate buffer was added to each well of a 96-well microwell plate (Nunc Maxisorp, San Diego, CA) and incubated overnight at 4 °C. Plates were washed 3 times with PBS-T (PBS with 0.05% Tween-20) and then blocked with 5% (w/v) BSA in PBS-T by incubation at room temperature for 1 h. After
washed 3 times with PBS-T, serum samples were added for 1 h and incubated at room temperature. Plates were washed 3 times with PBS-T again before addition of the secondary antibody (goat anti-turkey IgG [H + L]). Plates were washed again 3 times with PBS-T followed by addition of substrate (pNPP Microwell substrate system, Kirkegaard and Perry Laboratories, Gaithersburg, MD). The plates were incubated for 15 min in the dark and the reaction was terminated using 2 M H₂SO₄. Plates were read at 405 nm using BioTek Powerwave XS microplate ELISA reader (BioTek Instruments Inc., Winooski, VT). All combinations were repeated in triplicate to obtain antigen and antibody concentrations that provided the highest OD difference between the known-positive and known-negative serum samples with minimal background.

The cutoff value for the optimized TCoV-S54–395 ELISA was determined using OD₄₀₅ values obtained from 86 control positive serum samples (sera collected from poult 14 days or later after the start of an RT-PCR-confirmed infection with TCoV) with 73 control negative turkey sera. Receiving Operating Characteristics (ROC) curves were generated using an Excel spreadsheet-based analysis tool (Griener, 1995; Griener et al., 1995) and used to determine cutoff OD₄₀₅ values that provided optimal sensitivity and specificity for each ELISA.

2.8. Determination of TCoV seroprevalence in commercially reared turkeys

Field serum samples were obtained from Ontario turkey farms. Thirty samples were collected from each of 6 commercial meat turkey and 6 breeder turkey farms for a total of 360 field serum samples from Ontario. All samples were heat-inactivated at 56°C for 30 min before being used in the TCoV-S54–395-based recombinant ELISA. All 360 serum samples were also tested using a recombinant TCoV nucleocapsid protein-based antibody ELISA as described by Gomaa et al. (2008b).

2.9. Cross-reactivity of turkey sera with IBV assessed using a commercial IBV whole virus ELISA

The cross-reactivity of turkey sera against IBV antigens was assessed using commercially available IBV whole virus-coated ELISA plates (FlockChek™ Infectious Bronchitis Virus Antibody Test Kit, IDEXX, Westbrook, ME). The ELISA was carried out according to the manufacturer’s instructions with the minor modification that the turkey sera were only diluted 1:250 rather than 1:500 as is normally the case when testing chicken sera. A sub-sample of 168 of the 360 serum samples obtained to assess the seroprevalence of TCoV in Ontario commercial turkey flocks were also tested using the IDEXX kit. Seropositive or seronegative status as determined by the OD₄₀₅ value for the TCoV-S54–395-based ELISA at 0.111; primary antibodies (turkey serum samples) were diluted at 1:250 and the secondary goat anti-turkey IgG (H + L)-AP conjugate was diluted at 1:2000. Substrate reactions were stopped after 15 min.

2.10. Statistical analyses

Differences in TCoV seroprevalence between breeder and meat turkey flocks were tested with one-tailed t-tests assuming unequal variances. In all cases, differences were considered significant at p < 0.05. Correlation (r) and Spearman Rank Order Correlation coefficient (ρ) calculated using the Free Statistics Software (Wessa, 2008) were used to assess the correlation of OD₄₀₅ values, and the seropositive or seronegative status as determined by the various ELISAs.

3. Results

3.1. Cloning and expression of TCoV-S₅₄–₃₉₅ protein

The signal peptide at the 5’ end of the S1 subunit was removed and a fragment spanning nucleotides 160–1182 was amplified and cloned. After IPTG induced expression and purification of the GST fusion protein (Fig. 1, lanes 1–2), Western blot analysis using anti-GST antibodies detected the TCoV-S₅₄–₃₉₅–GST fusion protein at its expected molecular weight of approximately 67 kDa (Fig. 1, lanes 3–4). The purified and thrombin-cleaved TCoV-S₅₄–₃₉₅ protein had an apparent molecular weight of 38 kDa when visualized by SDS-PAGE. Convalescent sera obtained from turkey poults experimentally infected with TCoV-MG10 recognized the thrombin-cleaved recombinant TCoV-S₅₄–₃₉₅ protein on Western blots (Fig. 1, lane 5).

3.2. Optimization of TCoV-S₅₄–₃₉₅-based ELISA system and cutoff values

The optimized ELISA concentration of recombinant antigen for plate coating was 60 ng/μl (TCoV-S₅₄–₃₉₅), primary antibodies (turkey serum samples) were diluted at 1:250 and the secondary goat anti-turkey IgG (H + L)-AP conjugate was diluted at 1:2000. Substrate reactions were stopped after 15 min.

Using a two graph ROC analysis (Griener, 1995; Griener et al., 1995) based on 73 known-negative control serum samples and 86 serum samples from experimentally infected turkeys at 14, 21, 28, 35, and 42 days post-infection as positive control sera, we established the cutoff OD₄₀₅ value for the TCoV-S₅₄–₃₉₅-based ELISA at 0.111; serum samples testing above this OD value were considered positive while values at or below this value were considered negative. Using the OD₄₀₅ value of 0.111 yielded 95% sensitivity and 92% specificity for this ELISA (Fig. 2).

3.3. Seroprevalence of TCoV in Ontario, Canada

Using the TCoV-S₅₄–₃₉₅-based ELISA, presence of antibodies against TCoV was determined using 360 serum samples collected at random from 12 turkey farms (30 samples per farm). High seroprevalence rates were consistently observed on turkey breeder farms (Table 1) with a mean seroprevalence of 71.1 ± 0.51% (128/180 had OD₄₀₅ values >0.111). In serum samples obtained from meat turkey farms, significantly lower
Mean seroprevalence of 56.7 ± 2.33% (102/180 had OD405 values >0.111) was observed (Table 2).

### 3.4. Comparison of recombinant TCoV-N-based and TCoV-S54–395-based ELISAs

There was strong positive correlation between the two ELISAs when the results obtained from the 360 Ontario paired field samples were evaluated (Fig. 3). The data were highly positively correlated with respect to OD405 values (corrected $r = 0.880$; $p = 0.879$) and with respect to determination of TCoV seropositive or seronegative status (corrected $r = 0.836$) based on established OD405 cutoff.
values of 0.180 for the TCoV-N-based ELISA (see Gomaa et al., 2008b) and 0.111 for the TCoV-S54–395-based ELISA (present study).

### 3.5. Comparison of TCoV ELISAs to a commercial IBV whole virus ELISA for detecting seroconversion against TCoV

The ability of a commercial IBV whole virus-coated ELISA to detect antibodies recognizing TCoV was compared the TCoV-S54–395-based ELISA described herein and a previously described TCoV-N-based ELISA (Gomaa et al., 2008b). From 168 turkey serum samples tested, the two recombinant ELISAs produced TCoV seroprevalence rates that differed dramatically from the IBV-based ELISA; the IBV whole virus-coated ELISA revealed only 20.2% (17/84) positive samples from breeder turkey farms and 13.1% (11/84) positive samples from commercial turkey farms. In contrast, the recombinant antigen TCoV ELISAs reported much higher TCoV seroprevalence in both breeder turkey and meat turkey flocks (Fig. 4). The TCoV-S54–395-based ELISA detected overall seroprevalence of TCoV as 62.50% whereas the overall seroprevalence detected by the commercial IBV whole virus ELISA was 16.7%.

Both the Pearson product-moment correlation coefficient \( r \) and Spearman Rank Correlation coefficient \( \rho \) values confirmed that there was strong positive correlation between the two TCoV-specific recombinant antigen ELISAs (Table 3). However, there was much weaker positive correlation between the commercial IBV whole virus ELISA and either the TCoV-S54–395-based or TCoV nucleocapsid protein-based ELISAs. Interestingly, the Pearson product-moment correlation coefficient was modestly greater for the commercial IBV whole virus ELISA with the TCoV-N-based ELISA than with the TCoV-S54–395-based ELISA (Table 3).

### 4. Discussion

Enteric viruses continue to be found in commercial flocks of both chickens and turkeys in North America (Guy, 1998, 2000; Pantin-Jackwood et al., 2008). Turkey coronavirus is one of the most important etiological agents of diarrhoea in young turkey pouls (Cavanagh, 2005) and is believed to be involved in PEMS (Poul Enteritis and Mortality Syndrome). However, turkey coronavirus is rarely found within clinically normal turkey flocks because TCoV infections are frequently clinically apparent and thus readily diagnosed (Pantin-Jackwood et al., 2008) and subsequently eliminated through depopulation followed by disinfection (Guy, 1998). Detection of TCoV virus particles may be a poor indication of infection because of relatively short-lived virus shedding by infected animals.

Serological evidence for infection with TCoV has relied on one or more of the four major structural proteins of TCoV, including the nucleocapsid protein (N), the structural protein (S), the spike protein (S2), and the small G-protein (G). The nucleocapsid protein (N) is located in the viral core and is essential for viral genome packaging. The structural protein (S) mediates cell entry, and the spike protein (S2) is responsible for cell fusion and virus entry. The small G-protein (G) is involved in the regulatory function of the virus.

Table 3

|                  | TCoV-S54–395 | TCoV-N | IDEXX-IBV |
|------------------|--------------|--------|-----------|
| TCoV-S54–395     | 0.709d,e     | 0.182de|           |
| TCoV-N           | 0.879d,e     | 0.262e |           |
| IDEXX-IBV        | 0.217d,e     | 0.182d,e|           |

* See Gomaa et al. (2008b).
* IDEXX FlockChek® IBV-ELISA kit.
* Pearson product-moment correlation coefficient \( r \).
* Spearman Rank Correlation coefficient \( \rho \).
* Significant at \( p < 0.05 \).
produced by most coronaviruses: spike (S) glycoprotein, membrane (M) protein, small envelope (E) protein or nucleocapsid (N) protein. Most antibody ELISAs developed to identify serum antibodies against TCoV have relied on recombinant TCoV-N protein (e.g., Breslin et al., 2001; Guy et al., 2002; Loa et al., 2004; Gomaa et al., 2008b) or cross-reactivity to native IBV whole virus antigen (Loa et al., 2000). Unlike the N-protein, the spike glycoprotein, particularly the S1 subunit, varies considerably among strains of IBV (e.g., Gibertoni et al., 2005; Zhu et al., 2007) and TCoV (Gomaa et al., 2008a). The S1 region carries the receptor binding domain that defines tissue and host tropisms and the S1 region is responsible for serotype variability among IBV isolates (Cavanagh, 1983, 2005). Antibodies against the spike glycoprotein, particularly within hypervariable portions of the S1 region, have been shown to be responsible for virus neutralization and haemagglutination-inhibition of IBV (Kant et al., 1992; Ignjatovic and Galli, 1994). Presuming that the S1 region is equally important for a protective immune response against TCoV, measurement of antibodies specific for the S1 region of the spike protein might be expected to be a better predictor of flock protection against TCoV than assays dependent on antibodies cross-reacting against IBV whole virus antigen or specific for the more highly conserved TCoV nucleocapsid protein alone. Initially, we intended to clone and express the entire S1 protein of TCoV-MG10. However, as with IBV, the S1 protein of TCoV is characterized by presence of a signal peptide domain at the extreme 5’ end of the gene (Gibertoni et al., 2005) that was found to block successful cloning and expression of the complete S1 gene (data not shown). To overcome this, a fragment of the S gene was selected for cloning and expression based on B cell epitope prediction.

The recombinant TCoV-S<sub>54-395</sub>-based ELISA described in this study had high specificity and sensitivity as determined using a two graph ROC analysis and a strong positive correlation (Table 3 and Fig. 3) with a previously described ELISA based on recombinant TCoV-N protein (Gomaa et al., 2008b). In contrast, using the IDEXX FlockChek<sup>®</sup> IBV whole virus ELISA performed according to the manufacturer’s instructions and with the kit reagents (conjugated secondary antibody and enzyme substrate), only 16.7% of 168 field serum samples would be considered seropositive for TCoV: the two TCoV-specific ELISAs found that 70.24% (N-based) and 62.50% (TCoV-S<sub>54–395</sub>-based) of these same serum samples were positive for antibodies recognizing TCoV. There were positive, albeit weak, correlations of the commercial IBV-based ELISA with the two recombinant TCoV ELISAs (Table 3). Interestingly, the IBV-based ELISA OD readings had higher correlation with the TCoV-N-based ELISA (r = 0.262) than they did to the TCoV-S<sub>54–395</sub>-based ELISA (r = 0.190). Perhaps this is not surprising because the N-protein is relatively conserved and the S1 protein displays considerable heterogeneity among IBV and TCoV strains (e.g., McFarlane and Verma, 2008; McKinley et al., 2008) as well as between IBV and TCoV (Gomaa et al., 2008a). In contrast, there was strong positive correlation between the two recombinant ELISAs (r = 0.71; ρ = 0.879, Table 3). Assuming a typical turkey flock seroprevalence of TCoV of about 65% (Guy et al., 2002; Gomaa et al., 2008b), the TCoV-S<sub>54–395</sub>-based ELISAs would typically have a positive predictive value of 96% and negative predictive value of 94%. Similar values have been shown for the N-based ELISA recently described (Gomaa et al., 2008b). It is likely that the TCoV-S<sub>54–395</sub>-based ELISA would also be able to determine seroconversion of quail to a recently described enteric coronavirus (QCoV) because of its high amino acid identity in the S1 region with TCoV (Circella et al., 2007; Gomaa et al., 2008a).

Few epidemiological surveys have been conducted to determine TCoV seroprevalence. Using IFA or a commercially available (IDEXX) IBV-ELISA, it was determined that in Indiana, 175/325 (53.84%) or 163/325 (50.15%) field samples had antibodies for TCoV, respectively (Loa et al., 2000). In a second study using a competitive ELISA and a recombinant TCoV-N protein, 63% of sampled turkey pouls were found to possess antibodies to TCoV (Guy et al., 2002). Our recombinant TCoV-S<sub>54–395</sub>-based ELISA found 71.11% and 56.67% positive samples from Ontario breeder turkey and meat turkey flocks, respectively (Tables 1 and 2). The significantly higher prevalence in the turkey breeder flocks may result from the longer period over which these birds have had time to be exposed to TCoV and mount a detectable serum antibody response. The high seroprevalence of TCoV in commercial turkey flocks observed in this and previous studies (Loa et al., 2000; Guy et al., 2002) contrasts sharply with low prevalence of TCoV virus shedding observed in 33 commercial turkey flocks screened using an avian coronavirus RT-PCR technique (Pantin-Jackwood et al., 2008). This apparent discrepancy may indicate that TCoV may only shed for a relatively short period of time (Ismail et al., 2003; personal observations) and that subclinical infections with TCoV are much more common than was believed previously. Perhaps application of the recombinant TCoV ELISAs described in this paper and a previous report (Gomaa et al., 2008b) could be used to determine the onset of seroconversion in commercial flocks and associate this seroconversion with any changes in condition or performance of young pouls.

In summary, a serum ELISA was developed using the S1 region of the TCoV spike glycoprotein. The ELISA performed better in detecting antibodies against TCoV in turkey sera than commercially available IBV-ELISA kits and the recombinant antigen ELISA was valuable in detecting high seroprevalence of TCoV in breeder and meat turkey farms in Ontario, Canada.

Acknowledgements

We thank Tony Cengija and Barb Mitchell of the Campus Animal Facility’s Isolation Unit of the University of Guelph for the excellent care of our experimental animals and Stephanie Reabel and Inas Elawadli for assistance with animal handling and sample collection. We also thank Janet Swinton, Gaye Smith, Hongwen Fu, and Keith Harron of the University of Guelph’s Animal Health Laboratory for technical assistance and Jeff Zhang from Cold Spring Farms for the field turkey sera. Hybrid Turkeys (Kitchener, ON, Canada) generously donated day of age poult used in the
study. Dr. Billy Hargis, University of Arkansas, Fayetteville, AR, USA kindly provided SPF turkey serum samples. This work is supported by grants to JRB from the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Ontario Ministry of Agriculture and Food and Rural Affairs (OMAFRA). MG is a scholarship recipient from the Egyptian Cultural and Educational Bureau of the Arab Republic of Egypt in Canada.

References

Ali, A., Reynolds, D.L., 1998. The in vitro propagation of stunting syndrome agent. Avian Dis. 42, 657–666.

Breslin, J.J., Smith, L.G., Guy, J.S., 2001. Baculovirus expression of turkey coronavirus nucleocapsid protein. Avian Dis. 45, 136–143.

Cavanagh, D., 2005. The role of coronaviruses in enteric diseases of turkeys. http://www.poultry-health.com/ora/turkeyhealth/turtec24/cavanagh.htm.

Chou, P.Y., Fasman, G.D., 1987. Prediction of the secondary structure of proteins from their amino acid sequence. Adv. Enzyme. Relat. Areas Mol. Biol. 47, 45–148.

Circella, E., Camarda, A., Martella, V., Bruni, G., Lavazza, A., Buonavoglia, C., 2007. Coronavirus associated with an enteric syndrome on a quail farm. Avian Path. 36, 251–258.

Emini, E.A., Hughes, J.V., Perlow, D.S., Boger, J., 1985. Induction of hepatitis C virus-neutralizing antibody by a virus-specific synthetic peptide. J. Virol. 55, 836–839.

Gibertoni, A.M., Med, F., Montassier, J.A., Sena, P.E., Givisiez, C.R., Furuyama, Montassier, H.J., 2005. Development and application of Saccharomyces cerevisiae-expressed nucleocapsid protein based enzyme-linked immunosorbent assay for detection of antibodies against infectious bronchitis virus. J. Clin. Microbiol. 43, 1982–1984.

Gomaa, M.H., Barta, J.R., Ojkic, D., Yoo, D., 2008a. Complete genome sequence of turkey coronavirus. Virus Res. 135, 237–246.

Gomaa, M.H., Yoo, D., Ojkic, D., Barta, J.R., 2008b. Seroprevalence of turkey coronavirus in North American turkeys established using a newly developed recombinant antigen TCoV-specific antibody ELISA. Clin. Vacc. Immunol. 15, 1839–1844.

Guy, J.S., 1998. Virus infections of gastrointestinal tracts of poultry. Poult. Sci. 77, 1166–1175.

Guy, J.S., 2000. Turkey coronavirus is more closely related to avian infectious bronchitis virus than to mammalian coronaviruses: a review. Avian Path. 29, 207–212.

Guy, J.S., Barnes, H.J., Smith, L.G., Breslin, J.J., 1997. Antigenic characterization of a turkey coronavirus identified in poult enteritis- and mortality syndrome affected turkeys. Avian Dis. 41, 583–590.

Guy, J.S., Smith, L.G., Breslin, J.J., Pakpinyo, S., 2002. Development of a competitive enzyme-linked immunosorbent assay for detection of turkey coronavirus antibodies. Avian Dis. 46, 334–341.

Ignotjovic, J., Galli, L., 1994. The S1 glycoprotein but not N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens. Arch. Virol. 138, 117–134.

Ismaill, M.M., Tang, Y., Safi, Y.M., 2003. Pathogenicity of turkey coronavirus in turkeys and chickens. Avian Dis. 47, 522–1522.

Kant, A., Koch, G., van Roozelaar, D.J., Kusters, J.G., Poelwijk, F.A., van der Zeedt, R.A., 1992. Location of antigenic sites defined by neutralizing monoclonal antibodies on the S1 avian infectious bronchitis virus glycoprotein. J. Gen. Virol. 73, 591–596.

Kolaskar, A.S., Tongaonkar, P.C., 1990. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 276, 172–174.

Larsen, J.E., Lund, P.O., Nielsen, M., 2006. Improved method for predicting linear B-cell epitopes. Immun. Res. 2, 1–7.

Loa, C.C., Lin, T.L., Wu, C.C., Thomas, A., Bryan, H., Thacker, L., Hooper, T., Schrader, D., 2000. Detection of antibody to turkey coronavirus by antibody capture enzyme linked immunosorbent assay utilizing infectious bronchitis virus antigen. Avian Dis. 44, 498–506.

McFarlane, R., Verma, R., 2008. Sequence analysis of the gene coding for the S1 glycoprotein of infectious bronchitis virus (IBV) strains from New Zealand. Virus Genes 37, 351–357.

McKinley, E.T., Hilt, D.A., Jackwood, M.W., 2008. Avian coronavirus infections in young turkey poults. Avian Path. 38, 181–186.

Pantin-Jackwood, M.J., Day, J.M., Jackwood, M.W., Spackman, E., 2008. Enteric viruses detected by molecular methods in commercial chicken and turkey flocks in the United States between 2005 and 2006. Avian Dis. 52, 235–244.

Parker, J.M., Guo, D., Hodges, R.S., 1986. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and experimentally derived accessible sites. Biochemistry 25, 5425–5432.

Patel, B.L., Pomeroy, B.S., Gonder, E., Cronkite, C.E., 1976. Indirect immunofluorescence assay utilizing infectious bronchitis virus S1 glycoprotein expressed by a recombinant baculovirus. J. Gen. Virol. 79, 719–723.

Song, C.S., Lee, Y.J., Lee, C.W., Sung, H.W., Kim, J.H., Mo, I.P., I. Zymiyama, Y., Jang, H.K., Mikami, T., 1998. Induction of protective immunity in chickens vaccinated with infectious bronchitis virus S1 glycoprotein expressed by a recombinant baculovirus. J. Gen. Virol. 79, 719–723.

Tumlin, J.T., Pomeroy, B.S., Linder, R.K., 1957. Bluecomb disease of turkey. J. Virol. Demonstration of a filterable agent. J. Am. Vet. Med. Assoc. 130, 360–365.

Weiss, S.R., Martin, S.N., 2005. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 69, 635.

Wessa, P., 2008. Free Statistics Software, Office for Research Development and Education, version 1.1.23.1, http://www.wessa.net/.

Williams, K.A., Li, W., Sneed, L.W., Collinson, E.W., 1992. Comparative analyses of the nucleocapsid genes of several strains of infectious bronchitis virus and other coronaviruses. Virus Res. 25, 213–222.

Zhu, J.G., Qian, H.D., Zhang, Y.L., Hua, X.G., Wu, Z.L., 2007. Analysis of similarity of the S1 gene in infectious bronchitis virus (IBV) isolates in Shanghai, China. Arch. Med. Vet. 39, 223–227.